Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of rhuMAb Beta7 in moderate to severe ulcerative colitis
2011-000897-80Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing rhuMAb Beta7 (various doses) with Placebo (2 arms). Primary endpoint: Clinical remission at Week 10. Started Jun 2011; status: completed.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-000897-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000897-80.